Insight

Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy

Joseph Grossman/X

Oct 22, 2024, 14:57

Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy

Joseph Grossman, Vice President of Early Clinical Development at Agenus, shared a post on LinkedIn:

“The final version of our recent Cancer Discovery paper came out today “Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy”.
I couldn’t be prouder of our team at Agenus, or more excited for the future of oncology.”

Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

Authors: Dhan Chand, et al.

Joseph Grossman

AACR Agenus cancer cancer awareness cancer care Cancer Discovery Dhan Chand fight against cancer Global fight against cancer immunotherapy Joseph Grossman OncoDaily Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage